CMPX Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (CMPX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -17.0% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Compass Therapeutics, Inc.
Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.